Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Seizures 2Glioma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × perampanel × Clear all
NCT04497142 2024-08-05

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Dana-Farber Cancer Institute

Phase 1/2 Completed
12 enrolled 8 charts
CNS

Glioma, Seizures

NCT02363933 2018-04-27

Perampanel in Seizure Patients With Primary Glial Brain Tumors

Duke University

Phase 4 Completed
9 enrolled 9 charts
CNS

Brain Neoplasms, Seizures

Data powered by HemOnc (CC BY 4.0) Colophon âš¡